Details for Patent: 9,694,009

Title:	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Abstract:	The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
Inventor(s):	Kikuchi; Tetsuro (Tokushima, JP), Iwamoto; Taro (Princeton, NJ), Hirose; Tsuyoshi (Tokushima, JP)
Assignee:	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Filing Date:	Jun 08, 2016
Application Number:	15/176,464
Claims:	1. A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression incombination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising: administering to the patient an effective amount of a pharmaceutical composition which comprise(s) (a) a compound selected from aripiprazole or metabolite of aripiprazole wherein the metabolite of aripiprazole is selected from the group consisting of dehydroaripiprazole, DM-1451 and DM-1452 and a pharmaceutically acceptable carrier in combination with at least one other pharmaceutical composition, each comprising (b) at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram, and salts thereof. 2. A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms. Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising: administering to the patient an effective amount of a pharmaceutical composition comprising aripiprazole and a pharmaceutically acceptable carrier in combination with at least one other pharmaceutical composition, each comprising at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline and salts thereof. 3. A method of treating mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising: administering to the patient of an effective amount of a pharmaceutical composition comprising aripiprazole and a pharmaceutically acceptable carrier in combination with at least one other pharmaceutical composition, each comprising at least one serotonin reuptake inhibitor selected from escitalopram and salt thereof. 4. The method of claim 2, wherein at least one serotonin reuptake inhibitor is citalopram. 5. The method of any one of claims 1 to 4, wherein aripiprazole is anhydrous aripiprazole crystals B. 6. The method of any one claims 1 to 4, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier. 7. The method of any one claims 1 to 4, wherein the mood disorder is useful for the treatment of depression of major depressive disorder. 8. The method of any one of claims 1 to 4, wherein the mood disorder is useful for the treatment of major depressive disorder or dementia with depressive symptoms. 9. The method of any one of claims 1 to 4, wherein the mood disorder is useful for the treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels or mood disorder following head injury. 10. A method of treating a mood disorder selected from the group consisting of depression of major depressive disorder, dementia with depressive symptoms, major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptoms, senile dementia, mood disorders associated with cerebral blood vessels and mood disorders following head injury in a patient comprising: administering to the patient of an effective amount of pharmaceutical composition comprising at least one metabolite of aripiprazole selected from the group consisting of dehydroaripiprazole, DM-1451 and DM-1452 and a pharmaceutically acceptable carrier in combination with at least one other pharmaceutical composition, each comprising at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof. 11. The method of claim 10, wherein the at least one serotonin reuptake inhibitor is citalopram. 12. The method of claim 10, wherein the at least one serotonin reuptake inhibitor is escitalopram. 13. The method of any one of claims 10 to 12, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carder. 14. The method of any one of claims 10 to 12, wherein the mood disorder is useful for the treatment of depression of major depressive disorder. 15. The method of any one of claims 10 to 12, wherein the mood disorder is useful for the treatment of major depressive disorder or dementia with depressive symptoms. 16. The method of any one of claims 10 to 12, when the mood disorder is useful for the treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels or mood disorder following head injury.